<DOC>
	<DOCNO>NCT02605174</DOCNO>
	<brief_summary>This prospective randomized , double-blind , placebo-controlled study subject disable migraine ( Migraine Disability Assessment ( MIDAS ) score ≥ 11 ) .</brief_summary>
	<brief_title>Three Doses Lasmiditan ( 50 mg , 100 mg 200 mg ) Compared Placebo Acute Treatment Migraine</brief_title>
	<detailed_description>Subjects ask treat migraine attack study drug outpatient basis . Subjects provide dose card contain dose initial treatment second dose use rescue recurrence migraine . Each subject 's study participation consist screen visit ( Visit 1 ) telephone contact within 7 day confirm eligibility , Treatment Period 8 week , End-of-Study ( EoS ) visit ( Visit 2 ) within one week ( 7 day ) treat single migraine attack . The total time study approximately 11 week .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Able willing give write informed consent authorize HIPAA . 2 . Patients migraine without aura fulfil International Headache Society ( IHS ) diagnostic criterion 1.1 1.2.1 ( International Headache Classification ( ICHD ) 2004 ) . 3 . History disable migraine least 1 year . 4 . MIDAS score ≥11 . 5 . Migraine onset age 50 year . 6 . History 3 8 migraine attack per month ( &lt; 15 headache day per month ) . 7 . Male female , age 18 year . 8 . Females childbearing potential must use willing use highly effective form contraception ( e.g . combine oral contraceptive , intrauterine device ( IUD ) , abstinence vasectomized partner ) . 9 . Able willing complete electronic diary record detail migraine attack treat study drug . 1 . Any medical condition clinical laboratory test judgment Investigator make subject unsuitable study . 2 . Pregnant breastfeed woman . 3 . Women childbearing potential use willing use highly effective contraception . 4 . Known hypersensitivity lasmiditan excipient lasmiditan oral tablet , sensitivity ditan . 5 . History evidence hemorrhagic stroke , epilepsy condition place subject increase risk seizure . 6 . History recurrent dizziness and/or vertigo include benign paroxysmal positional vertigo ( BPPV ) , Meniere 's disease , vestibular migraine , vestibular disorder . 7 . History diabetes mellitus complication ( diabetic retinopathy , nephropathy neuropathy ) . 8 . History within previous three year current evidence abuse drug , prescription illicit , alcohol . 9 . History orthostatic hypotension syncope . 10 . Significant renal hepatic impairment . 11 . Subject imminent risk suicide ( positive response question 4 5 CSSRS ) suicide attempt within six month prior screen visit . 12 . Previous participation clinical trial . 13 . Participation clinical trial experimental drug device previous 30 day . 14 . Known Hepatitis B C HIV infection . 15 . History , within past 12 month , chronic migraine form primary secondary chronic headache disorder ( e.g . hemicrania continuum , medication overuse headache ) headache frequency ≥15 headache day per month . 16 . Use 3 dos per month either opiates barbiturate . 17 . Initiation change concomitant medication reduce frequency migraine episode within three ( 3 ) month prior Screening/Visit 1 . 18 . Subjects employee sponsor . 19 . Relatives , staff directly reporting , Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>